PRAXIS PRECISION MEDICINES INC (PRAX)

Sector: Health Care

    Home/Companies/PRAX/Annual Meeting

2026 Annual Meeting Analysis

PRAXIS PRECISION MEDICINES INC · Meeting: June 10, 2026

Policy v1.2high confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

3

Directors AGAINST

0

Say on Pay

AGAINST

Auditor

FOR

Director Elections

Election of Class III Directors

3 FOR
✓ FOR
Gregory Norden

Norden has served since 2019 and brings strong financial expertise (former CFO of Wyeth Pharmaceuticals) and relevant public company board experience; PRAX's 3-year total shareholder return of roughly +1,964% vastly exceeds the XBI (SPDR S&P Biotech ETF) benchmark by over 1,900 percentage points, well above the 65-point threshold required to trigger an against vote, and no overboarding, attendance, or independence concerns are present.

✓ FOR
Marcio Souza

Souza is the sitting CEO and serves as a director; applying the same TSR trigger as all other directors, PRAX's 3-year outperformance versus XBI (SPDR S&P Biotech ETF) of over 1,900 percentage points is far above the 65-point threshold required to trigger an against vote, so no TSR-based concern applies, and no overboarding or attendance issues are present.

✓ FOR
William Young

Young has served since 2016 and brings deep biotechnology operating and board experience; PRAX's extraordinary 3-year outperformance versus XBI (SPDR S&P Biotech ETF) of over 1,900 percentage points clears the 65-point threshold by a massive margin, and no overboarding, attendance, or independence concerns are identified.

All three Class III director nominees — Gregory Norden, Marcio Souza, and William Young — receive FOR votes. PRAX's 3-year total shareholder return of approximately +1,964% outperforms the XBI (SPDR S&P Biotech ETF) benchmark by roughly +1,903 percentage points, far exceeding the 65-percentage-point threshold that would be needed to trigger an against vote. No overboarding, attendance, independence, or qualification concerns were identified for any nominee.

Say on Pay

✗ AGAINST

CEO

Marcio Souza

Total Comp

$8,708,648

Prior Support

61%%

Prior say-on-pay support below 70% threshold (61% in 2025) with incomplete remediation300% bonus multiplier represents a discretionary payout that raises pay-for-performance structure concernsAnnual bonus program lacks a disclosed maximum cap, reducing accountability of the incentive design

The prior year say-on-pay vote received only 61% support — below the 70% threshold in our policy — and while the company engaged with shareholders and committed to adding performance-based stock awards starting in 2026, the core concern raised by investors (lack of performance-contingent equity) was not addressed in the 2025 compensation year itself, meaning the pay being voted on today still reflects the old structure. The compensation committee awarded a 300% bonus multiplier — three times the target — based largely on its own qualitative judgment about exceptional execution, applied under a program with no disclosed maximum cap on payouts, which means there was effectively no ceiling on how much executives could receive regardless of pre-set goals. Although PRAX's stock performance in 2025 was outstanding (up roughly 283% for the year) and the pipeline achievements were real, the incentive pay structure for 2025 did not include meaningful pre-set, objective performance conditions tied to specific measurable thresholds, making the above-target bonus payout difficult to distinguish from discretionary compensation dressed up as pay-for-performance.

Auditor Ratification

✓ FOR

Auditor

Ernst & Young LLP

Tenure

7 yrs

Audit Fees

$1,615,400

Non-Audit Fees

$107,723

Ernst & Young LLP has served as PRAX's auditor since 2019 (approximately 7 years), well below the 25-year tenure threshold that would raise concerns; non-audit fees (tax services of $107,723) represent only about 6.7% of audit fees ($1,615,400), comfortably below the 50% threshold; and Ernst & Young is a Big 4 firm appropriate for a company of PRAX's $8.9 billion market cap with no material restatements disclosed.

Overall Assessment

The 2026 PRAX annual meeting ballot contains three standard proposals: a director election, auditor ratification, and say-on-pay. All three Class III director nominees receive FOR votes given PRAX's extraordinary stock outperformance versus the XBI (SPDR S&P Biotech ETF) benchmark, and Ernst & Young LLP is straightforwardly ratifiable given low non-audit fees and appropriate tenure; however, the say-on-pay vote receives an AGAINST determination because last year's below-70% shareholder support was not fully remediated in the 2025 pay program itself, and the 300% bonus multiplier was awarded under a structure lacking a disclosed maximum cap and pre-set objective performance thresholds.

Filing date: April 30, 2026·Policy v1.2·high confidence

Compensation Peer Group

22 companies disclosed in 2026 proxy filing

ACADACADIA Pharmaceuticals Inc.
ALKSAlkermes plc
APLSApellis Pharmaceuticals, Inc.
ARWRArrowhead Pharmaceuticals, Inc.
RNAAvidity Biosciences, Inc.
AXSMAxsome Therapeutics, Inc.
BHVNBiohaven Ltd.
BBIOBridgeBio Pharma, Inc.
CORTCorcept Therapeutics, Incorporated
CYTKCytokinetics, Incorporated
DNLIDenali Therapeutics Inc.
HALOHalozyme Therapeutics, Inc.
IMVTImmunovant, Inc.
IONSIonis Pharmaceuticals, Inc.
JAZZJazz Pharmaceuticals plc
MDGLMadrigal Pharmaceuticals, Inc.
NBIXNeurocrine Biosciences, Inc.
NUVLNuvalent, Inc.
PTCTPTC Therapeutics, Inc.
RAREUltragenyx Pharmaceutical Inc.
VKTXViking Therapeutics, Inc.
XENEXenon Pharmaceuticals Inc.